ÂÜÀòÂÒÂ×

John Proudfoot is a Scientific Advisor at Collaborative Medicinal Development. John has over 25 years of experience in medicinal chemistry and has held various positions at Boehringer Ingelheim, including Director of Medicinal Chemistry and Senior Scientist. In their role as Director, John was responsible for leading the medicinal chemistry group and progressing early projects to the start of lead optimization. John worked closely with therapeutic area and assay development colleagues to develop new concepts and implement practical and efficient lead identification strategies. John has deep experience with the opportunities and pitfalls associated with high-throughput screening, fragment-based screening and analog design across multiple target classes and mechanisms. John also has line management responsibility for groups of up to 25 scientists.

John Proudfoot's educational career includes a PhD in Organic Chemistry from University College Dublin, where they focused on alkaloid synthesis with Professor Dervilla Donnelly. John also completed postdoctoral studies in natural product chemistry at Stanford University, where they studied the isolation and biosynthesis of marine sterols with Professor Carl Djerassi. Finally, they completed postdoctoral studies in drug metabolism at the University of California, San Francisco with Professor John Cashman.